RxDoctor Payments Data

Humberto Maldonado, MD

Internal Medicine · Austin, TXNPI 1598745259

Payments from drug & device makers

$3,626in general payments, 2019–2025

Across 227 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Novo Nordisk$573
  • Abbott$393
  • Lilly USA, LLC$313
  • Amgen$218
  • Boehringer Ingelheim$206
  • plus $710 from 17 others

What the payments were for

  • Food & beverage$3,614100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,626 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$160,716
Medicare patients
266
Services billed
5,907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin99$131,373
OzempicSemaglutide67$83,378
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$47,956
EliquisApixaban41$43,751
JanumetSitagliptin Phos/Metformin Hcl34$35,709
JanuviaSitagliptin Phosphate18$28,191
MounjaroTirzepatide22$24,240
TrulicityDulaglutide25$23,923
Rosuvastatin Calcium412$6,117
Icosapent Ethyl14$5,477
Ezetimibe200$4,665
SynthroidLevothyroxine Sodium76$3,962
Atorvastatin Calcium377$3,277
Losartan Potassium263$3,214
Levothyroxine Sodium255$3,032

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$206$131,37399 claims
Novo NordiskOzempic$573$83,37867 claims
Lilly USA, LLCMounjaro, Trulicity$313$48,16347 claims
GSKTrelegy Ellipta$1,214$47,95645 claims
PfizerEliquis$93$43,75141 claims
AbbVieSynthroid$86$3,96276 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →